In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 697-707

  Haglund, Caroline ^a   Åleskog, Anna ^a   Nygren, Peter ^a   Gullbo, Joachim ^a   Höglund, Martin ^a   Wickström, Malin ^a   Larsson, Rolf ^a   Lindhagen, Elin ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anticancer drug development; In vitro assays; Primary patient tumor cells; Toxicity testing

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; IMATINIB; MELPHALAN; MIDOSTAURIN; RAPAMYCIN; VINCRISTINE;

ADVERSE DRUG REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER PATIENT; CELL TYPE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG APPROVAL; DRUG INDICATION; DRUG SCREENING; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MYELOMA; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; SOLID TUMOR; TISSUE SECTION;

ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; EPITHELIAL CELLS; HUMANS; KIDNEY TUBULES, PROXIMAL; LYMPHOCYTES; MODELS, BIOLOGICAL; STEM CELLS;

EID: 84859785457     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1746-1     Document Type: Article

References (32)

1. Damia G, D'Incalci M (2009) Contemporary pre-clinical development of anticancer agents-what are the optimal preclinical models? Eur J Cancer 45:2768-2781
2. Voskoglou-Nomikos T, Pater JL, Seymour L (2003) Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9:4227-4239 (Pubitemid 37204044)
3. Peterson JK, Houghton PJ (2004) Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40:837-844 (Pubitemid 38519762)
4. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM et al (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:1424-1431 (Pubitemid 32522115)
5. Sharma SV, Haber DA, Settleman J (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature reviews 10:241-253
6. Li W, Lam M, Choy D, Birkeland A, Sullivan ME et al (2006) Human primary renal cells as a model for toxicity assessment of chemo-therapeutic drugs. Toxicol In Vitro 20:669-676 (Pubitemid 43816247)
7. Li AP, Bode C, Sakai Y (2004) A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells. Chem Biol Interact 150:129-136 (Pubitemid 39441299)
8. Bosanquet AG, Bell PB (2004) Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells. J Exp Ther Oncol 4:145-154 (Pubitemid 39079051)
9. Li W, Lam MS, Birkeland A, Riffel A, Montana L et al (2006) Cell-based assays for profiling activity and safety properties of cancer drugs. J Pharmacol Toxicol Methods 54:313-319 (Pubitemid 44636258)
10. Fridborg H, Jonsson E, Nygren P, Larsson R (1999) Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer 35:424-432 (Pubitemid 29151940)
11. Lindhagen E, Nygren P, Larsson R (2008) The fluorometric microculture cytotoxicity assay. Nat Protoc 3:1364-1369
12. Haglund C, Aleskog A, Hakansson LD, Hoglund M, Jacobsson S et al (2010) The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing. Toxicol Lett 194:102-107
13. Larsson R, Kristensen J, Sandberg C, Nygren P (1992) Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50:177-185
14. FDA (2010) http://dailymed.nlm.nih.gov/dailymed/about.cfm. Food and Drug Administration. Available via Food and Drug Administration http://dailymed.nlm. nih.gov/dailymed/about.cfm. Accessed October 2010
15. Ramström H (ed) (2009) Läkemedelsboken. 17 edn. Apoteket AB, Stockholm
16. FASS (ed) (2009) FASS. The Swedish Drug Compendium, Lä kemedelsindustriförenningen AB
17. Kintzel PE (2001) Anticancer drug-induced kidney disorders. Drug Saf 24:19-38
18. Wolf D, Rumpold H (2009) A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours. Drug Saf 32:1001-1015
19. Sanz M, Burnett A, Lo-Coco F, Lowenberg B (2009) FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr Opin Oncol 21:594-600
20. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809-1818
21. Lindhagen E, Eriksson A, Wickstrom M, Danielsson K, Grundmark B et al (2008) Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur J Haematol 81:344-353
22. Boehrer S, Ades L, Galluzzi L, Tajeddine N, Tailler M et al (2008) Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. Biochem Pharmacol 76:1417-1425
23. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ et al (2005) Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 106:2841-2848 (Pubitemid 41510762)
24. Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K et al (2009) Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16:281-294
25. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E et al (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105:54-60 (Pubitemid 40053063)
26. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456
27. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281 (Pubitemid 46849157)
28. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M et al (2009) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822-3829
29. EMEA EMA Document Number EMA/783677/2009. Accessed 2010/09/30 2010
30. Holbeck SL, Collins JM, Doroshow JH (2010) Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther 9:1451-1460
31. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ et al (2005) Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106:3777-3784 (Pubitemid 41739012)
32. Pessina A, Albella B, Bayo M, Bueren J, Brantom P et al (2003) Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci 75:355-367 (Pubitemid 37220283)